wellwoman
Irritable Bowel Drug Withdrawn
Filed in archive Digestive Health by Florence Cardinal on April 3, 2007
Irritable Bowel Drug Withdrawn
Pills - they come and they go, one day hailed as a life saving panacea, the next day withdrawn as a threat to life. Makes a person wonder just what is safe to take and what isn't.

The latest to go, as reported in the New York Times, is Zelnorm (tegasarod):
The maker of Zelnorm, a medicine that treats constipation-related irritable bowel syndrome, stopped selling the drug Friday after federal drug officials concluded that it might cause heart attacks and strokes.

eDrugs.com describes the drug this way:
Tegaserod is used to treat severe, chronic, irritable bowel syndrome (IBS) in women who have constipation as their main bowel problem (constipation-predominant). It is also used to treat chronic idiopathic constipation in patients less than 65 years of age.

But there were problems with this drug even before the latest news. This from Web MD:
The FDA says Zelnorm has been associated with serious cases of diarrhea as well as instances of ischemic colitis -- a medical condition where blood flow is reduced to the intestines.



Permalink: Irritable Bowel Drug Withdrawn
Tags: constipation  irritable  bowel  syndrome  Zelnorm  tegasarod  heart  attack  strokes  health  irritable+bowel 
Trackback: http://publish.creative-weblogging.com/publish/mt-tb.pl/61095
img Addthis img Ask img Blinklist img del.icio.us img Digg img Fark img Facebook img Google img Lycos img Ma.gnolia Add this page to Mister Wong Mr Wong img Netscape img Netvousz img Newsvine img Reddit img StumbleUpon img Slashdot img Tailrank img Technorati img Wink img Yahoo

Vote for Irritable Bowel Drug Withdrawn:

  • Currently 10.00/10
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
Rating: 10.00 out of 2 vote(s) cast.
 
Subscribe
Share It
RSSrss
See all blog subscribe options
Google google
What is RSS?
Yahoo! yahoo
Addthis Subscribe using any feed reader!
Bloglines Bloglines
Newsletter

TwitterFollow us on Twitter!